Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 104 of 5804
-
Breakthrough trial aims to prevent lung damage in tiniest newborns
Prevention Recruiting nowThe purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Phase: PHASE2 • Sponsor: OHB Neonatology Ltd. • Aim: Prevention
Last updated Jun 27, 2026 13:08 UTC
-
CAR-T therapy takes on standard care in lymphoma battle
Disease control CompletedThis is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline i…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New myeloma cocktail aims to outperform current standard
Disease control OngoingThis is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.
Phase: PHASE3 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug combo aims to stop liver Cancer's return in High-Risk patients
Disease control OngoingA global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Supercharged immune cells take aim at childhood cancers
Disease control OngoingThis study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. The cancer has either come back after treatment or did not respond to treatment. Because there is no standard treatm…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to improve multiple myeloma treatment before and after stem cell transplant
Disease control OngoingThis protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus the association of bortezomib, thalidomide and dexamethasone (VTd) as pre…
Phase: PHASE2 • Sponsor: European Myeloma Network B.V. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma in major trial
Disease control CompletedThis is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approxi…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug duo shows promise against tough uterine cancer
Disease control CompletedThe purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cord blood treatment shows promise for tough leukemia cases
Disease control OngoingAllogeneic hematopoietic stem cell transplantation is a life-saving procedure in patients with blood cancers. Cord blood (CB) represents an alternative source of stem cells, which is associated with a lower risk of relapse, especially in the presence of minimal residual disease i…
Phase: PHASE2 • Sponsor: Ciusss de L'Est de l'Île de Montréal • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Immunotherapy drug shows promise in preventing High-Risk skin cancer recurrence
Disease control CompletedThis is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
HIV shot could replace daily pills for those who skip doses
Disease control OngoingThe purpose of this study was to compare the efficacy, safety, and durability of two different strategies to treat participants with a history of sub-optimal adherence and control of their HIV infection: long-acting (LA) antiretroviral therapy (ART) and all-oral standard of care …
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Hope for NASH: new pill aims to reverse liver damage and prevent cirrhosis
Disease control OngoingA double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease
Phase: PHASE3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cocktail of drugs shows promise for tough lung cancer
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer. The primary stud…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can Metal-Stripping infusions save diabetic limbs and hearts?
Disease control OngoingTACT3a is a double blind, placebo-controlled, randomized trial to test a novel therapy, edetate disodium-based chelation of environmentally acquired toxic metals, to reduce cardiovascular events including amputation in high-risk diabetic patients.
Phase: PHASE3 • Sponsor: Mt. Sinai Medical Center, Miami • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Double-Drug attack shows promise against advanced melanoma
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advanced mel…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New biologic drug aims to ease joint pain and swelling in Tough-to-Treat psoriatic arthritis
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Gene therapy takes on deadly brain tumor
Disease control TerminatedThis is a non-randomized, open label, phase I/IIa, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a lentiviral vector…
Phase: PHASE1, PHASE2 • Sponsor: Genenta Science • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Can 3D breast imaging spot more dangerous cancers than standard mammograms?
Diagnosis OngoingRandomized trial comparing tomosynthesis plus synthetic 2D Mammography vs Digital Mammography in respect to incidence of advanced cancers (interval and following round) and interval cancers.
Phase: NA • Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Diagnosis
Last updated Jul 26, 2026 00:00 UTC
-
Triple-Drug attack aims to wipe out blood cancer cells
Disease control Recruiting nowThe purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Double transplant aims to cure diabetes in kids with weak immune systems
Disease control Recruiting nowThis study evaluates the efficacy of sequential transplantation of umbilical cord blood stem cells and islet cells in children with monogenic immunodeficiency type 1 diabetes mellitus. Umbilical cord blood stem cell transplantation will be performed first. Children with stable im…
Phase: NA • Sponsor: Children's Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC